Aspirin with or without statin in the treatment of endotheliitis, thrombosis, and ischemia in coronavirus disease
Rev. Soc. Bras. Med. Trop
; 53: e20200472, 2020. tab, graf
Artigo
em Inglês
| Sec. Est. Saúde SP, Coleciona SUS, LILACS
| ID: biblio-1136838
Biblioteca responsável:
BR1.1
ABSTRACT
Abstract INTRODUCTION:
In the genesis of coronavirus disease (COVID-19), there is a process of endotheliitis associated with thrombotic changes, no studies have reported the use of acetylsalicylic acid (ASA) as a possible therapeutic approach. Statins could potentiate the ASA therapy.METHODS:
This is a series of 14 cases with a laboratory-confirmed diagnosis of COVID-19. All patients underwent the ASA therapy. Those who had risk factors for vascular disease also underwent the high-potency statin therapy. When symptoms were totally or practically resolved, patients were discharged and advised to continue medications for a complementary time, according to the clinical evolution of each patient.RESULTS:
The mean age of monitored patients was 48.6 years. A total of 78.6% patients presented with at least one comorbidity, which could have contributed as a risk factor for a poor prognosis in the evolution of COVID-19. Four patients had secondary bacterial infections; three patients needed hospitalization. None of the cases progress to stage III, and all patients had remission of symptoms, with 100% survival.CONCLUSIONS:
the process of endothelial dysfunction in COVID-19 involves disseminated thrombosis, initially microvascular and later expansion into larger vessels. ASA could act as a secondary prophylaxis and prevent thrombosis from developing and reaching stage III of the disease. As this was a case series, we cannot provide definitive conclusions; however, this study allows us to formulate hypotheses and support clinical trials to evaluate benefits of the ASA therapy in the treatment of COVID-19.
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Brasil
Contexto em Saúde:
ODS3 - Meta 3.3 Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
Problema de saúde:
Pneumonía
Base de dados:
LILACS
/
Sec. Est. Saúde SP
/
Coleciona SUS
Assunto principal:
Pneumonia Viral
/
Trombose
/
Aspirina
/
Infecções por Coronavirus
/
Inibidores de Hidroximetilglutaril-CoA Redutases
/
Inflamação
/
Isquemia
Tipo de estudo:
Estudo prognóstico
/
Fatores de risco
Limite:
Humanos
Idioma:
Inglês
Revista:
Rev. Soc. Bras. Med. Trop
Ano de publicação:
2020
Tipo de documento:
Artigo
Instituição/País de afiliação:
Hospital Metropolitano Sul Dom Hélder Câmara/BR
/
Universidade Federal de Pernambuco/BR